These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27557783)

  • 1. Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
    Di Desidero T; Derosa L; Galli L; Orlandi P; Fontana A; Fioravanti A; Marconcini R; Giorgi M; Campi B; Saba A; Lucchesi S; Felipetto R; Danesi R; Francia G; Allegrini G; Falcone A; Bocci G
    Invest New Drugs; 2016 Dec; 34(6):760-770. PubMed ID: 27557783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
    Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
    Briasoulis E; Aravantinos G; Kouvatseas G; Pappas P; Biziota E; Sainis I; Makatsoris T; Varthalitis I; Xanthakis I; Vassias A; Klouvas G; Boukovinas I; Fountzilas G; Syrigos KN; Kalofonos H; Samantas E
    BMC Cancer; 2013 May; 13():263. PubMed ID: 23718900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
    Jeong Y; Lee JL
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
    Parimi S; Eliasziw M; North S; Trudeau M; Winquist E; Chi KN; Ruether D; Cheng T; Eigl BJ
    Invest New Drugs; 2016 Dec; 34(6):771-776. PubMed ID: 27565809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
    Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
    Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
    Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
    Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
    Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
    Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
    BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.
    Saloustros E; Kalbakis K; Vardakis N; Kalykaki A; Milaki G; Rovithi M; Agelaki S; Saridaki Z; Georgoulias V; Mavroudis D
    J BUON; 2011; 16(2):215-8. PubMed ID: 21766488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
    Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
    Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].
    Grenader T; Plotkin Y; Rosengarten O
    Harefuah; 2014 Dec; 153(12):731-4, 752. PubMed ID: 25654915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.